Bibliographic citations
Flores, C., (2014). Detección de SNP en genes CYP2C8 de pacientes con cáncer de mama que reciben paclitaxel en el Instituto Nacional de Enfermedades Neoplásicas de marzo a diciembre 2013 [Tesis, Universidad Nacional Mayor de San Marcos]. https://hdl.handle.net/20.500.12672/3917
Flores, C., Detección de SNP en genes CYP2C8 de pacientes con cáncer de mama que reciben paclitaxel en el Instituto Nacional de Enfermedades Neoplásicas de marzo a diciembre 2013 [Tesis]. PE: Universidad Nacional Mayor de San Marcos; 2014. https://hdl.handle.net/20.500.12672/3917
@misc{renati/1223305,
title = "Detección de SNP en genes CYP2C8 de pacientes con cáncer de mama que reciben paclitaxel en el Instituto Nacional de Enfermedades Neoplásicas de marzo a diciembre 2013",
author = "Flores Fernández, Carol Nathali",
publisher = "Universidad Nacional Mayor de San Marcos",
year = "2014"
}
--- The aim of this study was to detect the frequency of CYP2C8*2 and CYP2C8*3 single nucleotide polymorphisms (SNP) in CYP2C8 genes of patients with breast cancer who received neoadjuvant chemotherapy with paclitaxel at the National Institute of Neoplastic Diseases (INEN). Furthermore, the presence of these SNP with therapeutic response and toxicity were associated. In the study were included 39 women with newly diagnosed of locally advanced breast cancer who attended the oncology doctor’s office of the INEN between March and December 2013. All the patients signed informed consent before study entry. Venous blood samples were taken to extract the genomic DNA and specific regions of the CYP2C8 gene were amplified by Polymerase Chain Reaction (PCR) with primers designed to detect the CYP2C8*2 SNP in exon 5 and CYP2C8*3 SNP in exon 8. The amplified products were cut with restriction enzymes BclI and PdmI (XmnI) for CYP2C8*2 and CYP2C8*3, respectively. Clinical and pathological information of the patients was obtained from the medical records stored at the INEN. The CYP2C8*2 SNP was not detected in the study population. The CYP2C8*3 SNP was found in 3 patients (7.7%), two homozygotes and one heterozygote, with an allele frequency of 6.4%. Also, it was found that 56.5% of patients had neuropathy; 10.3% leukopenia; 20.5% anemia; 2.6% thrombocytopenia; 66.7% increase in ALT levels and 46.2% increase in AST levels. No association between CYP2C8*3 genotype and risk of paclitaxel induced neuropathy (p> 0.05) was found. The patients who had the AA genotype for CYP2C8*3 (1196 A>G) showed significant differences in the reduction of clinical tumor size and nodal involvement after chemotherapy with paclitaxel (p <0.05). However, patients with AG and GG genotypes for this SNP showed no significant differences. Keywords: Breast cancer, CYP2C8 gene, SNP, PCR-RFLP.
This item is licensed under a Creative Commons License